A phase I/II study of concurrent chemoradiotherapy with irinotecan for advanced or recurrent uterine cancer.

Trial Profile

A phase I/II study of concurrent chemoradiotherapy with irinotecan for advanced or recurrent uterine cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2012

At a glance

  • Drugs Irinotecan (Primary) ; Antineoplastics
  • Indications Uterine cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top